Is Zepbound Approved for Weight Loss?

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Zepbound (tirzepatide) became the first dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA specifically for weight loss in 2023. Clinical trials showed participants on tirzepatide lost an average of 22% of body weight over 68 weeks. PlexusDx provides access to compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan through licensed 503A pharmacies, serving all 50 states without insurance requirements.

How Zepbound Works for Weight Loss

Zepbound's active ingredient, tirzepatide, activates two hormone receptors in the brain that regulate appetite and blood sugar. The GIP receptor helps control hunger signals, while the GLP-1 receptor slows stomach emptying and increases feelings of fullness. Together, these actions reduce calorie intake naturally, making sustained weight loss more achievable without severe dietary restriction.

The dual-receptor mechanism differs from older single-GLP-1 medications like Wegovy (semaglutide). In head-to-head trials, tirzepatide consistently outperformed semaglutide for weight loss, with some participants reaching 22% body weight reduction compared to 17% with semaglutide alone. This superior efficacy has made tirzepatide the preferred first-line choice for many patients seeking maximum weight loss results.

FDA Approval and Clinical Evidence for Tirzepatide

The FDA granted approval to Zepbound on November 8, 2023, based on the SURMOUNT clinical trial program. The largest trial enrolled over 2,500 participants with obesity across 18 countries and showed sustained weight loss, improved cardiovascular markers, and better blood sugar control. Participants maintained their weight loss for up to two years of continuous treatment, demonstrating long-term safety and efficacy.

Zepbound approval required participants to have a body mass index (BMI) of 30 or higher, or BMI of 27 or higher with at least one weight-related condition such as type 2 diabetes, hypertension, or sleep apnea. The injectable formulation comes in five dose strengths ranging from 2.5 mg to 15 mg, with dose adjustments made every four weeks under medical supervision based on individual tolerance and response.

Zepbound vs. Compounded Tirzepatide from PlexusDx

While Zepbound is the brand-name version dispensed by major pharmacies, PlexusDx offers compounded tirzepatide injections through licensed 503A compounding pharmacies at a significantly lower cost. Compounded medications contain the same active pharmaceutical ingredient as brand-name drugs but are prepared in-house by state-licensed pharmacists rather than mass-manufactured. Both deliver equivalent therapeutic outcomes when sourced from accredited compounders.

PlexusDx's compounded tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) with no insurance requirement, no membership fees, and HSA/FSA eligibility. Brand-name Zepbound typically costs $1,000–$1,500 monthly out-of-pocket after insurance, making compounded options accessible to far more patients. PlexusDx also allows dose adjustments without price increases—your dose may need to go up, but your price won't.

Personalized Treatment with Genetic Testing

Individual responses to tirzepatide vary significantly based on genetics. Some patients achieve 30% body weight loss, while others reach 15%—both considered successful outcomes. PlexusDx offers the Precision Peptide Genetic Test ($298) to identify how your genetics influence GIP and GLP-1 receptor function, appetite regulation through MC4R and FTO pathways, and overall peptide metabolism across 14 biological pathways.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Common Side Effects and Safety Considerations

Tirzepatide's most frequent side effects include nausea, vomiting, constipation, and diarrhea, primarily occurring during the dose-escalation phase. These gastrointestinal effects typically resolve within 1–2 weeks as the body adapts. Serious adverse events are rare but include pancreatitis, thyroid concerns in susceptible individuals, and gallbladder complications in patients with prior gallstone history.

Zepbound carries a black-box warning regarding thyroid C-cell tumors based on animal studies, though no human cases have been confirmed. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use tirzepatide. PlexusDx physicians conduct thorough health screening before prescribing and monitor patients throughout treatment to ensure safety and efficacy.

Who Is a Good Candidate for Tirzepatide Weight Loss?

FDA-approved candidates for tirzepatide have a BMI of 30 or higher, or BMI of 27 or higher with weight-related medical conditions. However, clinical judgment extends beyond BMI—patients with metabolic dysfunction, insulin resistance, or strong family histories of obesity may benefit even at lower BMI thresholds. PlexusDx evaluates each patient's health history, current medications, and weight loss goals to determine if tirzepatide is appropriate.

Tirzepatide is not recommended for pregnant individuals, those with personal or family thyroid cancer history, or patients with uncontrolled diabetes or severe kidney disease. Success requires commitment to lifestyle changes including balanced nutrition and physical activity; medication alone does not guarantee results. Combining tirzepatide with behavioral modifications and regular medical oversight produces the best long-term weight loss and health improvements.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Zepbound the same as compounded tirzepatide from PlexusDx?

Both contain identical active tirzepatide but differ in manufacture and cost. Zepbound is mass-produced by pharmaceutical manufacturer Eli Lilly and sold through traditional pharmacies at $1,000–$1,500 monthly. PlexusDx's compounded tirzepatide is prepared by licensed 503A pharmacists and costs $289 per month with no insurance needed, delivering the same clinical results at substantially lower cost.

How much weight can I expect to lose on tirzepatide?

No — the Precision Peptide Genetic Test does not predict your response to Zepbound or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I use my HSA or FSA to pay for PlexusDx tirzepatide?

Yes, PlexusDx compounded tirzepatide injections are HSA/FSA eligible, allowing you to use pre-tax health savings. Additionally, no insurance is required, and there are no membership fees—making PlexusDx accessible whether you have coverage or not.

What are the most common side effects of tirzepatide?

Nausea, vomiting, constipation, and diarrhea occur most frequently during dose escalation and typically resolve within 1–2 weeks. Serious side effects are rare but may include pancreatitis or gallbladder complications. PlexusDx physicians monitor you throughout treatment and adjust dosing strategies if side effects persist.

How does the Precision Peptide Genetic Test help with tirzepatide treatment?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy Vs Zepbound Weight Loss
• Zepbound For Weight Loss
• Maxlife Weight Loss
• Remedy Meds Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.